Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2001 / Cilt: 27 - Sayı: 4

Intermittent maximum androgen blockade in advanced prostate cancer

İleri evre prostat kanserli hastalarda aralıklı maksimum androjen blokajı

Pages
417–423
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intermittent androgen blockade (IAB) for advanced prostate cancer was initially intended to prolong the overall period of androgen dependence, the time course of the disease until progression and- to improve the quality of life.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intermittent androgen blockade (IAB) for advanced prostate cancer was initially intended to prolong the overall period of androgen dependence, the time course of the disease until progression and- to improve the quality of life.
📊
Key Findings & Data:Maximum androgen blockade was initiated for 3 months.
💡
Conclusion & Impact:The present results indicate that IAB appears to be a feasible treatment alternative, which enables increase in libido and recovery of sexual function during off therapy periods in patients with advanced prostate cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Androjenler · Prostat neoplazmları · Yaşam kalitesi

Abstract

Intermittent androgen blockade (IAB) for advanced prostate cancer was initially intended to prolong the overall period of androgen dependence, the time course of the disease until progression and- to improve the quality of life. This study was undertaken to assess the feasibility of IAB and to present the clinical outcome of. patients who were treated with IAB. Fifteen previously untreated patients with locally advanced or metastatic prostate cancer were treated using IAB. Hormonal treatment options were explained and with the patients' consent IAB was instituted to the patients, especially who wish to participate in an international IAB study protocol. Maximum androgen blockade was initiated for 3 months. Hormonal therapy was ceased in patients whose PSA falls >80% of the initial value or <4 ng/ml. At the off hormone therapy period patients were followed clinically and with PSA. Therapy is restarted when PSA is >10 ng/ml or the patient is symptomatic; or when PSA is >20 ng/ml and the patient is asymptomatic. Time to tumor progression, progression free survival, treatment free period and quality of life issues were evaluated. The patients received mean 2.5 cycles (range, 1-8) of hormone therapy. The mean time to PSA nadir or >80% decrease was 8.8 weeks (range, 4-14). The mean of treatment period was 55% for the entire therapy period. After a mean of 20.8 months, 4 (57%) of the7 patients with metastatic disease and 4 (50%) of the 8 patients with locally advanced disease progressed to an androgen independent state. After a median 40 months follow-up, progression-free and overall survival were 22±3.4 months (range, 8-46) and 41.6±4 months (range, 18-72), respectively. Ten (66%) patients had reported an increase of libido and recovery of sexual function during off therapy periods, after a median 8 weeks following cessation of androgen blockade. The present results indicate that IAB appears to be a feasible treatment alternative, which enables increase in libido and recovery of sexual function during off therapy periods in patients with advanced prostate cancer.

Özet

İleri evre prostat kanserli hastalarda aralıklı androjen blokajı (AAB), androjen bağımsız hale geçme süresini geciktirmek, progresyona kadar geçen süreyi uzatabilmek ve yaşam kalitesini iyileştirebilmek düşüncesiyle ortaya çıkmıştır. Bu çalışmada AAB ile elde ettiğimiz klinik sonuçları ve tedavinin uygulanabilirliğini değerlendirmek amaçlanmıştır. Daha önce tedavi görmemiş, lokal invaziv veya metastatik, prostat kanserli hastalara, hormonal tedavi seçenekleri anlatıldıktan sonra, uluslararası bir tedavi protokolü çerçevesinde uygulanmakta olan AAB tedavisi hakkında bilgi verilerek, bu çalışma içinde yer almak isteyen 15'ine AAB protokolü uygulandı. Üç ay süreyle yapılan maksimal androjen blokajı sonrası serum PSA düzeyi <4 ng/ml olanlar veya ilk PSA değeri %80'in altına inen hastalarda tedavi kesildi. Hastalar tedavisiz dönemde klinik muayene ve PSA ile izlendi. Serum PSA değeri $\geq$10 ng/ml ve semptomatik progresyonu olan veya asemptomatik olup PSA $\geq$20 ng/ml olan hastalara tedavi tekrar başlandı. Progresyonsuz sağkalım, tedavisiz periyod, progresyona kadar geçen süre ve yaşam kalitesi değerlendirildi. Hastalara ortalama 2.5 (1-8) tedavi siklüsü uygulandı. MAB sonrası PSA taban değere ulaşıncaya veya %80'den fazla azalma oluncaya kadar geçen zaman ortalama 8.8 (4-14) hafta olarak bulundu. Hastalar, toplam tedavi siklüslerinin ortalama %55'inde tedavi almadılar. Metastatik olan 7 hastanın 4'ünde (%57), ve lokal ileri evre olan 8 hastanın 4'ünde (%50), ortalama 20.8 ayda hormonal tedaviye direnç gelişti. Ortanca 40 aylık izlem sonunda progresyonsuz sağkalım 22±3.4 ay (8-46), toplam sağkalım 41.6±4 ay (18-72) olarak gerçekleşti. On hastada (%66) tedavi verilmeyen sürede libidonun ve cinsel aktivitenin, ortanca 8 hafta içinde geri döndüğü gözlendi. İleri evre prostat kanserli hastalarda AAB, kolay uygulanabilir ve tedavisiz süre boyunca libido ve cinsel aktivitenin geri dönmesine olanak sağlayan bir tedavi seçeneği izlenimi vermektedir.

🔖

Cite This Article

TÜZEL, E., KIRKALI, Z., TURGUT, T., MUNGAN, M. U. (2001). Intermittent maximum androgen blockade in advanced prostate cancer. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 27 - Sayı: 4, 417–423. https://ajindex.com/articles/328599

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. O'Reilly KJ, Crawford ED, Trasher JB: Com-bined androgen blockade: Current conroversies. Intermittent/early versus late; in Vogelzang NJ, Scardino PT, Shipley WU, Joffey DS (eds). Gen-tito Urinary Oncology, Philadelphia, Lippincott Williams and Wilkins, pp. 842-854, 2000
  2. Gleave ME, Bruchovsky N, Goldenberg SL, et al: Intermittent androgen suppression: Rationale and clinical experience; in Schröder F (ed). Re-cent advances in prostate cancer and BPH, Lon-don, Parthenon, pp. 109-121, 1997
  3. Tyrell CJ: Controversies in the management of advanced prostate cancer. Brit J Cancer. 79: 146-155, 1999 4- Bruchovsky N, Rennie PS, Coldman AJ, et al: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50:2275-82, 1990
  4. Gleave ME, Hsieh JT, Wu HC, et al: Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52: 1598, 1992
  5. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen dependent tumors. Apoptosis and se-rum prostate specific antigen. Cancer. 71: 2782-90, 1993
  6. Klotz LH, Herr HW, Morse MJ, et al: Intermit-tent endocrine therapy for advanced prostate can-cer. Cancer. 58: 2546-50, 1986
  7. Goldenberg SL, Bruchovsky N, Gleave ML, et al: Intermittent androgen suppression in the treat-ment of prostate cancer: A preliminary report. U-rology. 45: 839-44, 1995
  8. Higano CS, Ellis W, Russell K, et al: Intermit-tent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Uro-logy. 48: 800-4, 1996
  9. Gleave ML, Bruchovsky N, Goldenberg SL, et al: Intermittent androgen suppression: Rationale and clinical experience. Eur Urol. 34 (suppl 3): 37-41, 1998
  10. Oliver RT, Williams G, Paris AM, et al: Inter-mittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hor-mone resistant prostate cancer. Urology. 49: 79-82, 1997
  11. Horwich A, Huddart RA, Gadd J, et al: A pilot study of intermittent androgen deprivation in ad-vanced prostate cancer. Brit J Urol. 81: 96-99, 1998
  12. Grossfeld GD, Small EJ, Carroll PR: Intermit-tent androgen deprivation for clinically localized prostate cancer: Initial experience. 51: 137-144, 1998
  13. Crook JM, Szumacher E, Malone S, et al: In-termittent androgen suppression in the manage-ment of prostate cancer. Urology. 53: 530-534, 1999
  14. Kurek R, Renneberg H, Lübben G, et al: Inte